These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33512849)

  • 41. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE; Park TE; Kalabalik J; Gupta R
    Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings.
    Marcus JL; Volk JE; Pinder J; Liu AY; Bacon O; Hare CB; Cohen SE
    Curr HIV/AIDS Rep; 2016 Apr; 13(2):116-24. PubMed ID: 26898645
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.
    Lehman DA; Baeten JM; McCoy CO; Weis JF; Peterson D; Mbara G; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Frenkel L; Ndase P; Mugo NR; Celum C; Overbaugh J; Matsen FA;
    J Infect Dis; 2015 Apr; 211(8):1211-8. PubMed ID: 25587020
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam.
    Hoornenborg E; Achterbergh RC; van der Loeff MFS; Davidovich U; van der Helm JJ; Hogewoning A; van Duijnhoven YT; Sonder GJ; de Vries HJ; Prins M;
    J Int AIDS Soc; 2018 Mar; 21(3):e25105. PubMed ID: 29603900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.
    Jain S; Krakower DS; Mayer KH
    Clin Infect Dis; 2015 Jun; 60 Suppl 3(Suppl 3):S200-4. PubMed ID: 25972505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implementation of pre-exposure prophylaxis at a community pharmacy through a collaborative practice agreement with San Francisco Department of Public Health.
    Lopez MI; Cocohoba J; Cohen SE; Trainor N; Levy MM; Dong BJ
    J Am Pharm Assoc (2003); 2020; 60(1):138-144. PubMed ID: 31405804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes.
    Duwal S; Dickinson L; Khoo S; von Kleist M
    PLoS Comput Biol; 2018 Jun; 14(6):e1006155. PubMed ID: 29902179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
    Dolling D; Phillips AN; Delpech V; Pillay D; Cane PA; Crook AM; Shepherd J; Fearnhill E; Hill T; Dunn D; ;
    HIV Med; 2012 May; 13(5):309-14. PubMed ID: 22151684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.
    Moodley D; Lombard C; Govender V; Naidoo M; Desmond AC; Naidoo K; Mhlongo O; Sebitloane M; Newell ML; Clark R; Rooney JF; Gray G;
    Lancet HIV; 2023 Mar; 10(3):e154-e163. PubMed ID: 36746169
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
    Thaden JT; Gandhi M; Okochi H; Hurt CB; McKellar MS
    AIDS; 2018 Jun; 32(9):F1-F4. PubMed ID: 29683856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-exposure prophylaxis completion and condom use in the context of potential sexual exposure to HIV.
    Gantner P; Allavena C; Duvivier C; Cabie A; Reynes J; Makinson A; Ravaux I; Bregigeon S; Cotte L; Rey D;
    HIV Med; 2020 Aug; 21(7):463-469. PubMed ID: 32558205
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission.
    Koole JC; de la Court F; Welkers MR; Yap K; Stalenhoef JE; Jurriaans S; de Vries HJ; Op de Coul EL; Prins M; Hoornenborg E
    Euro Surveill; 2022 Apr; 27(14):. PubMed ID: 35393931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2022 Jul; 17(4):213-221. PubMed ID: 35762376
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Associations between self-test and pre- or post-exposure prophylaxis of HIV among men who have sex with men in China.
    Wang X; Hu X; Liu Z; Hui H
    Int J STD AIDS; 2022 Aug; 33(9):837-846. PubMed ID: 35786144
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of the Early COVID-19 Pandemic on the Number of HIV Preexposure Prophylaxis Uses and the Proportion of Preexposure Prophylaxis Users Receiving Sexually Transmitted Infection Testing Services.
    Schmidt MA; Salas SB; Donald JL; Gift TL; Tao G
    Sex Transm Dis; 2023 May; 50(5):304-309. PubMed ID: 36730891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Uptake and outcomes of a novel community-based HIV post-exposure prophylaxis (PEP) programme in rural Kenya and Uganda.
    Ayieko J; Petersen ML; Kabami J; Mwangwa F; Opel F; Nyabuti M; Charlebois ED; Peng J; Koss CA; Balzer LB; Chamie G; Bukusi EA; Kamya MR; Havlir DV
    J Int AIDS Soc; 2021 Jun; 24(6):e25670. PubMed ID: 34152067
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differences in Awareness of Pre-exposure Prophylaxis and Post-exposure Prophylaxis Among Groups At-Risk for HIV in New York State: New York City and Long Island, NY, 2011-2013.
    Walters SM; Rivera AV; Starbuck L; Reilly KH; Boldon N; Anderson BJ; Braunstein S
    J Acquir Immune Defic Syndr; 2017 Jul; 75 Suppl 3():S383-S391. PubMed ID: 28604443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
    Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
    Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
    Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.